
Brief intro:
- Author: Xin He, Yue Xie, Qiongping Zheng, Zeyu Zhang, Shanshan Ma, Junyu Li, Mingtao Li, and Qiaoying Huang
- Journal: Front Cell Dev Biol
- Doi: https://www.doi.org/10.3389/fcell.2021.761773
- Publication Date: 2021 Nov 29
Products/Services used in the paper
Quotation shows PackGene:rAAV2/9-hSyn-EGFP-miR30a-shTfe3-WPRE (AAV-shTFE3) was used to target murine Tfe3 gene and rAAV2/9-hSyn-EGFP-miR30ashScramble-WPREs (AAV-shScr) was used as a control. The Tfe3 shRNA sequence was 5′-GCGACAGAAGAAAGACAATCA-3’. The scrambled shRNA sequence was 5′-CCTAAGGTTAAGTCGCCCTCG-3′, non-target in mice. All the viruses were generated and packaged by BrainVTA (Wuhan, China) and PackGene Biotech.
Research Field:CNS
AAV Serotype:rAAV2/9
Targeted organ:Dopaminergic Neurons in brain
Animal or cell line strain:C57BL/6 mice
Abstract
Impairment of autophagy has been strongly implicated in the progressive loss of nigral dopaminergic neurons in Parkinson's disease (PD). Transcription factor E3 (TFE3), an MiTF/TFE family transcription factor, has been identified as a master regulator of the genes that are associated with lysosomal biogenesis and autophagy. However, whether TFE3 is involved in parkinsonian neurodegeneration remains to be determined. In this study, we found decreased TFE3 expression in the nuclei of the dopaminergic neurons of postmortem human PD brains. Next, we demonstrated that TFE3 knockdown led to autophagy dysfunction and neurodegeneration of dopaminergic neurons in mice, implying that reduction of nuclear TFE3 may contribute to autophagy dysfunction-mediated cell death in PD. Further, we showed that enhancement of autophagy by TFE3 overexpression dramatically reversed autophagy downregulation and dopaminergic neurons loss in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) model of PD. Taken together, these findings demonstrate that TFE3 plays an essential role in maintaining autophagy and the survival of dopaminergic neurons, suggesting TFE3 activation may serve as a promising strategy for PD therapy.
About PackGene
PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.
